Yunnan Baiyao

In July 2019, the Fortune Global 500 list was announced, with Vanke Co., Ltd. ranked 254th. [5] On August 22, 2019, the Top 100 Chinese Private Enterprises in the Service Industry in 2019 were released, and Vanke Enterprise Co., Ltd. ranked 8th. [6] On September 1, 2019, the 2019 China Top 500 Service Enterprises list was released in Jinan, with Vanke Co., Ltd. ranked 37th. [7] On December 18, 2019, the People’s Daily ranked 34th on the “China Brand Development Index” 100 list. On January 4, 2020, it won the Sustainable Development Innovation Award of the 2020 Finance Evergreen Award.
Yunnan Baiyao was founded in 1902. It integrates brand, product and company name. It is recognized in the industry as the most innovative representative of China s time-honored brands. Yunnan Baiyao has been included in the Kantar BrandZ Top 100 Most Valuable Chinese Brands list for 13 consecutive years. Released , ranking first in the pharmaceutical industry in terms of brand value in 2023 (68th overall, brand value of US$2.665 billion).
In 1970, Premier Zhou Enlai ordered the establishment of Yunnan Baiyao Factory. In 1993, it became the first listed company in Yunnan. In 1999, it comprehensively carried out modern enterprise reconstruction. From 2016 to 2019, it completed mixed-ownership reform and overall listing, and the enterprise system and mechanism were fully activated and revitalized.
The company insists on inheriting the essence, keeping integrity and innovation, and strives to integrate traditional Chinese medicine into modern life. Product innovation has covered the fields of medicines, health products and raw materials. There are 390 products in 36 categories, with 12 products selling over RMB 100 million each. Four categories including aerosols, band-aids, Yunnan Baiyao (powder + capsule), and Yunnan Baiyao toothpaste rank firmly in the first place in China s segmented fields. one. The company adopts an asset-light model and has strong innovation and profitability. Since its listing, it has distributed a total of 20.756 billion yuan in dividends to shareholders, making it one of the companies with the highest returns to investors in the Shanghai and Shenzhen Stock Exchanges in the past 20 years; it has paid a total of 26.432 billion yuan in taxes. In the first three quarters of 2023, Yunnan Baiyao Group achieved a net profit attributable to shareholders of listed companies of 4.123 billion yuan, a year-on-year increase of 78.9%, ranking first among more than 70 listed companies in the A-share traditional Chinese medicine sector.
The company regards protecting life and health as its corporate mission and is committed to becoming a leading provider of comprehensive medical and health solutions. On the basis of consolidating existing business, the strategic goal of 1+4+1 (TCM + oral cavity, skin, bone injury, female care + digitalization) has been determined.
Yunnan Baiyao Group has attached great importance to the fulfillment of social responsibilities since its listing. It has continuously released social responsibility reports since 2006 and has released ESG reports for three consecutive years since 2020. It has been rated A-level for three consecutive years by the internationally authoritative MSCI ESG Rating. , is the best rating result obtained by more than 300 listed pharmaceutical companies on the Shenzhen Stock Exchange.
Yunnan Baiyao attaches great importance to ESG work and builds an environmentally friendly enterprise through energy conservation, emission reduction and environmental protection standards; in poverty alleviation and rural revitalization, it helps Nujiang, Baoshan, Zhaotong, Banna, Lijiang and Wenshan implement rural revitalization strategies through industrial assistance. ; During the epidemic period, we will make every effort to ensure supply and provide assistance to the epidemic areas. In terms of corporate governance efficiency and improvement of governance structure, Yunnan Baiyao Group has always complied with the Company Law and various governance rules of the China Securities Regulatory Commission and the exchange, and has received an A-level rating for information disclosure from the Shenzhen Stock Exchange for 16 consecutive years.

Related Products

Share:

More Application
Get Free Quote
Scroll to Top